Less than a year after it was forced to withdraw GBT's sickle cell disease (SCD) therapy Oxbryta from all world markets after ...

Novo Nordisk's GLP-1 drugs have been under considerable competitive pressure in the last few months, so the company will be ...

Precigen has won approval in the US for a first-in-class immunotherapy for recurrent respiratory papillomatosis (RRP), a rare ...

The deal – which has a total value of up to $1.3 billion including an unspecified upfront payment – gives Bayer exclusive ...

Following the first-ever FDA approval of a TIL therapy in the U.S., and with regulatory decisions pending in Canada and ...

The 9th MASH Drug Development Summit is the essential forum for pharmaceutical giants and innovative biotechs dedicated to ...

In another sign of increased regulatory scrutiny of vaccines in the US, Health and Human Services (HHS) Secretary Robert F ...

The complicated legal wrangling has been brought to a close after CureVac and BioNTech settled their mRNA patent litigation ...

Yantai-based RemeGen said it will now move ahead with filing telitacicept with China's National Medical Products ...

The approval of ArteraAI Prostate by the FDA as a software as a medical device (SaMD) means it can now be used at the point ...

At ASCO 2025 in Chicago, pharmaphorum web editor Nicole Raleigh spoke with Dr Jason Williams, director of interventional ...

“Sexuality and intimacy are important aspects of quality of life and may also reduce some of the psychosocial distress ...